Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

NCT02055781 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

311

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis

Interventions

DRUG: Pacritinib
DRUG: Best Available Therapy

Sponsor

CTI BioPharma